Literature DB >> 12665368

Equilibrium, 1H and 13C NMR spectroscopy, and X-ray diffraction studies on the complexes Bi(DOTA)- and Bi(DO3A-Bu).

Eva Csajbók1, Zsolt Baranyai, István Bányai, Erno Brücher, Róbert Király, Anke Müller-Fahrnow, Johannes Platzek, Bernd Radüchel, Martina Schäfer.   

Abstract

Several Bi(III) complexes are used in medicine as drugs. Bi(DO3A-Bu) has recently been proposed as a nonionic contrast agent in X-ray imaging (H(3)DO3A-Bu = 10-[2,3-dihydroxy-(1-hydroxymethyl)propyl]-1,4,7,10-tetraazacyclododecane-1,4,7,-triacetic acid). The solution equilibria and NMR structure and dynamics of Bi(DO3A-Bu) and of the similar Bi(DOTA)(-) have been investigated (H(4)DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid). The stability constants were determined with the study of the competition equilibria between Br(-) ions and the ligands DOTA or DO3A-Bu for the Bi(III) by spectrophotometry. The stability constants, obtained for Bi(DOTA)(-) and Bi(DO3A-Bu), are very high, log K = 30.3 and 26.8, respectively. Potentiometric titrations indicated the dissociation of one of the protons among the three alcoholic OH groups in Bi(DO3A-Bu). The dissociation constant is log K = 7.53 (0.09) indicating that at physiological pH about 50% of the species possess -1 charge. It was shown by (1)H and (13)C NMR spectroscopy that the OH group attached to the middle carbon atom of the "butriol" side chain is coordinated to the Bi(III) and starts to deprotonate at pH > 5.5. The crystal structure of NaBi(DOTA).H(2)O shows an octacoordinated arrangement of the donor atoms around the Bi(III), with no water in the inner sphere. The crystals belong to the centrosymmetric space group C2/c. The temperature dependent (1)H and (13)C NMR spectra indicate that both Bi(DOTA)(-) and Bi(DO3A-Bu)(-) complexes are fluxional. For Bi(DOTA), the Delta(deltadeltadeltadelta) right harpoon over left harpoon Lambda(lambdalambdalambdalambda) fluxionality was identified, and on the basis of the activation parameters, a synchronous motion was suggested for the fluxional motion resulting in the change of ring conformation and of the helicity of the complex. The transition state is supposed to be more symmetrical than the initial state. The deprotonated Bi(DO3A-Bu) has a highly asymmetric NMR structure in solution, and its fluxional motion is slower than that of Bi(DOTA)(-).

Entities:  

Year:  2003        PMID: 12665368     DOI: 10.1021/ic0261272

Source DB:  PubMed          Journal:  Inorg Chem        ISSN: 0020-1669            Impact factor:   5.165


  10 in total

1.  Ultrasmall Silica-Based Bismuth Gadolinium Nanoparticles for Dual Magnetic Resonance-Computed Tomography Image Guided Radiation Therapy.

Authors:  Alexandre Detappe; Eloise Thomas; Mark W Tibbitt; Sijumon Kunjachan; Oksana Zavidij; Nishita Parnandi; Elizaveta Reznichenko; François Lux; Olivier Tillement; Ross Berbeco
Journal:  Nano Lett       Date:  2017-02-02       Impact factor: 11.189

2.  Analysis of the isomer ratios of polymethylated-DOTA complexes and the implications on protein structural studies.

Authors:  Ana Christina L Opina; Madeleine Strickland; Yong-Sok Lee; Nico Tjandra; R Andrew Byrd; Rolf E Swenson; Olga Vasalatiy
Journal:  Dalton Trans       Date:  2016-02-09       Impact factor: 4.390

3.  Structure and properties of DOTA-chelated radiopharmaceuticals within the 225Ac decay pathway.

Authors:  Artem R Khabibullin; Aleksandra Karolak; Mikalai M Budzevich; Mark L McLaughlin; David L Morse; Lilia M Woods
Journal:  Medchemcomm       Date:  2018-06-06       Impact factor: 3.597

Review 4.  Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside.

Authors:  Stephen Ahenkorah; Irwin Cassells; Christophe M Deroose; Thomas Cardinaels; Andrew R Burgoyne; Guy Bormans; Maarten Ooms; Frederik Cleeren
Journal:  Pharmaceutics       Date:  2021-04-21       Impact factor: 6.321

5.  Theoretical Study of Actinide(III)-DOTA Complexes.

Authors:  Attila Kovács
Journal:  ACS Omega       Date:  2021-05-11

6.  First-Generation Bispidine Chelators for 213 BiIII Radiopharmaceutical Applications.

Authors:  Frank Bruchertseifer; Peter Comba; Bodo Martin; Alfred Morgenstern; Johannes Notni; Miriam Starke; Hubert Wadepohl
Journal:  ChemMedChem       Date:  2020-07-02       Impact factor: 3.466

7.  Facile transmetallation of [SbIII(DOTA)]- renders it unsuitable for medical applications.

Authors:  Catherine Chen; Charlotte Sommer; Helge Thisgaard; Vickie McKee; Christine J McKenzie
Journal:  RSC Adv       Date:  2022-02-16       Impact factor: 3.361

Review 8.  AGuIX® from bench to bedside-Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine.

Authors:  François Lux; Vu Long Tran; Eloïse Thomas; Sandrine Dufort; Fabien Rossetti; Matteo Martini; Charles Truillet; Tristan Doussineau; Guillaume Bort; Franck Denat; Frédéric Boschetti; Goran Angelovski; Alexandre Detappe; Yannick Crémillieux; Nathalie Mignet; Bich-Thuy Doan; Benoit Larrat; Sébastien Meriaux; Emmanuel Barbier; Stéphane Roux; Peter Fries; Andreas Müller; Marie-Caline Abadjian; Carolyn Anderson; Emmanuelle Canet-Soulas; Penelope Bouziotis; Muriel Barberi-Heyob; Céline Frochot; Camille Verry; Jacques Balosso; Michael Evans; Jacqueline Sidi-Boumedine; Marc Janier; Karl Butterworth; Stephen McMahon; Kevin Prise; Marie-Thérèse Aloy; Dominique Ardail; Claire Rodriguez-Lafrasse; Erika Porcel; Sandrine Lacombe; Ross Berbeco; Awatef Allouch; Jean-Luc Perfettini; Cyrus Chargari; Eric Deutsch; Géraldine Le Duc; Olivier Tillement
Journal:  Br J Radiol       Date:  2018-09-18       Impact factor: 3.039

9.  A Radionuclide Generator of High-Purity Bi-213 for Instant Labeling.

Authors:  Stanislav Ermolaev; Aino Skasyrskaya; Aleksandr Vasiliev
Journal:  Pharmaceutics       Date:  2021-06-21       Impact factor: 6.321

Review 10.  212Pb: Production Approaches and Targeted Therapy Applications.

Authors:  Konstantin V Kokov; Bayirta V Egorova; Marina N German; Ilya D Klabukov; Michael E Krasheninnikov; Antonius A Larkin-Kondrov; Kseniya A Makoveeva; Michael V Ovchinnikov; Maria V Sidorova; Dmitry Y Chuvilin
Journal:  Pharmaceutics       Date:  2022-01-13       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.